Lasa Supergenerics Limited has issued a regulatory intimation regarding a scheduled meeting of its Board of Directors. The meeting is scheduled to be held on Saturday, November 14, 2026.
The primary agenda for the board meeting includes:
- Consideration, approval, and taking on record of the unaudited financial results of the Company for the quarter and half year ended September 30, 2026
- Review of the Limited Review Report issued by the Statutory Auditor of the Company regarding these financial results
- Discussion of any other matters with the permission of the Chairperson
The disclosure is made pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
In accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company's Code of Conduct, the trading window for securities shall continue to remain closed until 48 hours after the declaration of the unaudited financial results for the quarter and half year ended September 30, 2026.
This intimation is also available on the company's website at www.lasalabs.com and on the websites of the stock exchanges at www.bseindia.com and www.nseindia.com.
The document is signed by Omkar Herlekar, Chairman and Managing Director of Lasa Supergenerics Limited.